Gilead Sciences, Inc. (GILD) Shares Sold by Cannell Peter B & Co. Inc.
Cannell Peter B & Co. Inc. lowered its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 2.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 48,780 shares of the biopharmaceutical company’s stock after selling 1,095 shares during the quarter. Cannell Peter B & Co. Inc.’s holdings in Gilead Sciences were worth $3,766,000 at the end of the most recent reporting period.
Several other large investors have also added to or reduced their stakes in GILD. Reilly Financial Advisors LLC boosted its stake in Gilead Sciences by 98.3% during the third quarter. Reilly Financial Advisors LLC now owns 1,420 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 704 shares during the last quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors bought a new position in Gilead Sciences during the second quarter valued at approximately $132,000. Brand Asset Management Group Inc. bought a new position in Gilead Sciences during the second quarter valued at approximately $139,000. TRUE Private Wealth Advisors bought a new position in Gilead Sciences during the third quarter valued at approximately $174,000. Finally, Wealthsource Partners LLC bought a new position in Gilead Sciences during the second quarter valued at approximately $206,000. Hedge funds and other institutional investors own 78.09% of the company’s stock.
GILD opened at $71.18 on Friday. The firm has a market cap of $92.99 billion, a price-to-earnings ratio of 11.20, a PEG ratio of -2.79 and a beta of 1.01. Gilead Sciences, Inc. has a 52 week low of $64.27 and a 52 week high of $89.54. The company has a current ratio of 3.45, a quick ratio of 3.39 and a debt-to-equity ratio of 1.09.
The business also recently declared a quarterly dividend, which will be paid on Friday, December 28th. Stockholders of record on Friday, December 14th will be issued a $0.57 dividend. The ex-dividend date is Thursday, December 13th. This represents a $2.28 dividend on an annualized basis and a dividend yield of 3.20%. Gilead Sciences’s dividend payout ratio is presently 26.64%.
A number of brokerages recently commented on GILD. Morgan Stanley increased their price target on Gilead Sciences from $81.00 to $85.00 and gave the company an “equal weight” rating in a research note on Thursday, July 26th. Piper Jaffray Companies set a $85.00 price target on Gilead Sciences and gave the company a “buy” rating in a research note on Wednesday, September 12th. Mizuho set a $94.00 price target on Gilead Sciences and gave the company a “buy” rating in a research note on Thursday, November 1st. Zacks Investment Research lowered Gilead Sciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 25th. Finally, Raymond James dropped their price target on Gilead Sciences from $97.00 to $94.00 and set a “strong-buy” rating for the company in a research note on Friday, October 26th. Twelve investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $87.84.
In other news, Director John C. Martin sold 50,000 shares of Gilead Sciences stock in a transaction on Tuesday, September 4th. The stock was sold at an average price of $74.16, for a total value of $3,708,000.00. Following the transaction, the director now directly owns 3,067,762 shares in the company, valued at approximately $227,505,229.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold a total of 150,000 shares of company stock worth $11,087,500 over the last quarter. Company insiders own 1.30% of the company’s stock.
Gilead Sciences Profile
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Featured Story: Risk Tolerance
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.